The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 40230207 · doi:10.1111/dom.16366
What was done
Authors conducted a systematic review and meta-analysis across Medline, Embase, Cochrane Library, and Web of Science searching for randomized controlled trials (RCTs) evaluating the effects of GLP-1 receptor agonists (GLP-1 RAs) compared to placebo or conventional diabetes therapies on inflammatory biomarkers in patients with type 2 diabetes. Biomarkers investigated were CRP, TNF-α, IL-6, IL-1β, leptin, adiponectin, PAI-1, MCP-1, and AGEs. The analysis pooled 52 RCTs comprising 4,734 participants (median follow-up 24 weeks, mean age 54.13 years, 44.46% females, mean BMI 29.80 kg/m², mean HbA1c 8.28%, diabetes duration 7.27 years).
What was found
Compared to placebo or conventional diabetes therapies, GLP-1 RAs resulted in significant reductions in CRP (SMD -0.63, 95% CI [-1.03, -0.23]), TNF-α (SMD -0.92, 95% CI [-1.57, -0.27]), IL-6 (SMD -0.76, 95% CI [-1.32, -0.20]), IL-1β (SMD -3.89, 95% CI [-6.56, -1.22]), and leptin (SMD -0.67, 95% CI [-1.09, -0.26]). GLP-1 RAs also produced a significant increase in adiponectin (SMD 0.69, 95% CI [0.19, 1.19]). Effect sizes for PAI-1, MCP-1, and AGEs were not reported in the abstract.
Why it matters
This review synthesizes trial data showing that GLP-1 RAs exert systematic anti-inflammatory effects alongside glycemic control in patients with type 2 diabetes.
Limits
The abstract pools heterogeneous comparators (placebo, oral medications, and insulin) without reporting separated sub-analyses. Several pre-specified markers (PAI-1, MCP-1, AGEs) lack reported numerical findings in the abstract, and wide confidence intervals for certain outcomes (such as IL-1β) indicate substantial variability across included trials.
Cited by
- supports GLP-1 receptor agonist medications significantly reduce systemic inflammation.